• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioElectronics president outlines four-part growth strategy

BioElectronics president outlines four-part growth strategy

August 4, 2014
CenterWatch Staff

In a letter to shareholders, Andrew J. Whelan, president of BioElectronics, emphasized a four-part growth strategy initiated in the last year. 

The first initiative is a global marketing program. Sales of ActiPatch Therapy products are steadily increasing in Boots, the dominant pharmacy chain in the U.K. The successful sales growth experience at Boots will facilitate and accelerate getting ActiPatch Therapy in more retail outlets around the world. Boots pharmacies are a strategic member of the Boots-Alliance, a global pharmacy-led health and well-being enterprise that includes Walgreens, the largest drugstore chain in the U.S.

The second initiative was in developing political and public support to induce the FDA to recognize BioElectronics’ therapeutic solutions. In February, FDA recommendations included Physical Medicine Devices; Reclassification and Renaming of Shortwave Diathermy for All Other Uses. By reclassifying this technology to reflect its safety and efficacy, the FDA appears to be making scientific evidence the determinant for additional market clearances, not out-dated categorizations. 

Once the FDA finally makes a ruling, the company plans to submit new 510(K) applications with extensive clinical data. With the new FDA approach to classification, the company is hopeful that it will get equivalent U.S. market clearances to those earned in Canada and the European Common Market.

The third initiative involved continuing clinical research to further substantiate clinical efficacy and establish more indications of use. Since the last company shareholder report, BioElectronics has successfully completed three clinical studies, some observational studies and collected a growing body of consumer testimonials and pain data. The double-blind, placebo-controlled studies were for osteoarthritis of the knee, long-term plantar fasciitis and lower back pain.

The fourth and final initiative focused on lowering costs of capital to finance expansion. There are a number of potential applications of BioElectronics’ underlying technology that has had to put on the back burner because of resource issues. One way to reduce the cost of capital is by partnering in specific key markets with companies that have established sales and marketing presence.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing